Although the FDA does not have a hand in the regulation of drug prices, the safeguarding of access to medications is a crucial factor in the agency’s goal to foster and protect public health.
According to the ACR, a practical benefit of the guidance is that in situations where a biosimilar is not considered interchangeable, a pharmacist must ask the prescribing physician for a new prescription before switching a patient to or from a reference biologic.
Read Now
Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.